ITOS iTeos Therapeutics Inc.

FDA Catalyst Company
19.04
+0.74  (+4%)
Previous Close 18.3
Open 18.83
52 Week Low 16.94
52 Week High 52.43
Market Cap $676,379,530
Shares 35,524,135
Float 23,345,726
Enterprise Value $-183,157,572
Volume 127,544
Av. Daily Volume 482,959
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/13/2022
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 12/13/2021
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/12/2021
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 08/13/2021
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/19/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/05/2021
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/06/2021
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/19/2020
Baird Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 10/08/2020
JP Morgan Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 08/18/2020

Latest News

    • Enrolling patients with multiple myeloma in clinical trial of anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A in monotherapy and in combination with BMS's novel CELMoD agent, iberdomide.

    • Enrolling patients in the biomarker cohort in an ongoing clinical trial of inupadenant, an A2A receptor antagonist, as a monotherapy in patients with solid tumors expressing high levels of A2A to explore observed relationship between A2A levels and clinical benefit

    • Presented updated preclinical and clinical analyses at AACR 2022 supporting the multifaceted mechanism of action of EOS-448 and providing the first evidence of target engagement in the tumors of patients treated with an anti-TIGIT antibody

    • Cash balance of $824.0MM as of March 31, 2022, providing
    View Full Article
    • Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect in the tumors of patients treated with an anti-TIGIT antibody

    • In preclinical studies and in blood samples from patients with advanced cancers, treatment with EOS-448 results in a reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune system effector functions

    WATERTOWN, Mass. and GOSSELIES, Belgium, April 08, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of potentially differentiated immuno-oncology therapeutics for…

    View Full Article
  1. - Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab-gxly) and EOS-448 combination trial and announced plans to initiate multiple registration-directed clinical trials with this combination

    - Initiating trials combining EOS-448 and Jemperli in triplet regimens with inupadenant and GSK's investigational anti-CD96 antibody, GSK6097608

    - Advanced clinical development of inupadenant, EOS-850, an A2A receptor antagonist, start of expansion studies in PD-1 resistant melanoma in combination with pembrolizumab as well as a study further exploring novel predictive biomarkers

    - Cash balance of $848.5MM as of December 31, 2021, providing runway into 2026 to support clinical development

    View Full Article
  2. CAMBRIDGE, Mass. and GOSSELIES, Belgium, March 01, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. ET.

    A live webcast of the virtual presentation will be available on the Investors section of the company's website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

    About iTeos Therapeutics, Inc.

    View Full Article
  3. CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in two upcoming virtual investor conferences in February:

    11th Annual SVB Leerink Global Healthcare Conference
    Date: Thursday, February 17, 2022
    Time: 12:00 p.m. ET

    Citi's 2022 Virtual Immuno-Oncology Summit
    Date: Thursday, February 17, 2022
    Time: 1:30 p.m. ET

    A live webcast of the events will be available on the Investors section of the company's website at https://www.iteostherapeutics.com

    View Full Article
View All iTeos Therapeutics Inc. News